Abstract

The purpose of the study was to evaluate the fibroblast growth factor 21 levels (FGF-21) in blood plasma and the liver parenchyma state in non-alcoholic fatty liver disease (NAFLD) patients with hypertension. Materials and methods. 60 NAFLD patients aged 30 to 60 years were examined. The average age of the patients was (50.1 ± 6.9) years. The control group consisted of 20 practically healthy volunteers. All the patients were diagnosed with NAFLD, traditionally examined by clinical and laboratory methods, assessed for trophological status and lipid metabolism. The determination of FGF-21 was performed by the immune enzyme method in blood plasma using ELISA kits. Results. Evaluation of the liver parenchyma state demonstrated that in patients with NAFLD and hypertension, the F2-3 stage of fibrosis predominated in 60 % of cases. Depending on the existing stage of fibrosis, there was an increase in the liver enzymatic activity (P < 0.05, except the comparison results in patients with F0 and F1 stages), lipid profile (P < 0.001) and HOMA index (P < 0.05). An increase in the level of FGF-21 was detected in all NAFLD patients with hypertension and 3.4 times (P = 0.001) exceeded the parameters of practically healthy persons as well as its dependence on the stage of the liver fibrotic changes (P < 0.05, except the comparison results in patients with F1 and F2-3 stages). The correlations revealed confirm the pathogenetic relationship between FGF-21 and the liver inflammation development (P < 0.05). Conclusions. The FGF-21 levels in the blood plasma of NAFLD patients with hypertension exceed the parameters of the control group, are higher with increasing degree of liver fibrosis and associated with metabolic disorders in patients. The results obtained characterize the cytokine FGF-21 as a promising predictor marker for NAFLD progression.

Highlights

  • Evaluation of the liver parenchyma state demonstrated that in patients with non-alcoholic fatty liver disease (NAFLD) and hypertension, the F2-3 stage of fibrosis predominated in 60 % of cases

  • Depending on the existing stage of fibrosis, there was an increase in the liver enzymatic activity (P < 0.05, except the comparison results in patients with F0 and F1 stages), lipid profile (P < 0.001) and HOMA index (P < 0.05)

  • An increase in the level of fibroblast growth factor 21 levels (FGF-21) was detected in all NAFLD patients with hypertension and 3.4 times (P = 0.001) exceeded the parameters of practically healthy persons as well as its dependence on the stage of the liver fibrotic changes (P < 0.05, except the comparison results in patients with F1 and F2-3 stages)

Read more

Summary

Introduction

Оцінювання стану паренхіми печінки показало, що у хворих на НАЖХП на тлі ГХ переважала стадія фіброзу печінки (ФП) F2–3 – 60 % випадків. Залежно від стадії ФП визначили зростання ферментативної активності печінки (р < 0,05, крім порівняння результатів хворих зі стадіями F0 та F1), показників ліпідного профілю (р < 0,001) та НОМА-індексу (р < 0,05). Підвищення рівня FGF-21 виявили в усіх хворих на НАЖХП на тлі ГХ, в яких він був більшим за показник практично здорових осіб у 3,4 раза (р = 0,001). Виявили також його підвищення залежно від стадії фібротичних змін у печінці (р < 0,05, крім порівняння результатів хворих зі стадіями F1 та F2–3). Рівні FGF-21 у плазмі крові хворих на НАЖХП на тлі ГХ перевищують показники групи контролю, зростають зі збільшенням ступеня фіброзу печінки та асоціюються з порушенням ліпідного та вуглеводного метаболізму хворих. The purpose of the study was to evaluate the fibroblast growth factor 21 levels (FGF-21) in blood plasma and the liver parenchyma state in non-alcoholic fatty liver disease (NAFLD) patients with hypertension

Objectives
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.